OverviewSuggest Edit

Portola Pharmaceuticals is a biopharmaceutical company. It develops therapies to treat thrombosis and other hematologic diseases. Portola is dedicated to the discovery and development of medicines for patients with thrombosis and hematologic cancers. The Company provides two medicines: Andexxa and Bevyxxa.
TypePublic
Founded2003
HQSouth San Francisco, CA, US
Websiteportola.com
Employee Ratings3.3
Overall CultureC+

Latest Updates

Employees (est.) (Dec 2018)324(+29%)
Revenue (FY, 2019)$116.6 M(+191%)
Share Price (Jul 2020)$18
Cybersecurity ratingAMore

Key People/Management at Portola Pharmaceuticals

Scott Garland

Scott Garland

President and Chief Executive Officer, Director
Mardi C. Dier

Mardi C. Dier

Executive Vice President, Chief Financial Officer and Chief Business Officer
Sheldon Koenig

Sheldon Koenig

Executive Vice President, Chief Commercial Officer
Ernie Meyer

Ernie Meyer

Executive Vice President, Chief Human Resources Officer
John Moriarty

John Moriarty

Executive Vice President, General Counsel and Secretary
Glenn Brame

Glenn Brame

Executive Vice President, Chief Technical Operations Officer
Show more

Portola Pharmaceuticals Office Locations

Portola Pharmaceuticals has offices in South San Francisco, Planegg and Amsterdam
South San Francisco, CA, US (HQ)
270 E Grand Ave
Planegg, DE
Fraunhoferstraße 12
Amsterdam, NL
Prins Bernhardplein 200
Show all (3)

Portola Pharmaceuticals Financials and Metrics

Portola Pharmaceuticals Revenue

Portola Pharmaceuticals's revenue was reported to be $116.64 m in FY, 2019
USD

Revenue (Q1, 2020)

26.4m

Gross profit (Q1, 2020)

22.1m

Gross profit margin (Q1, 2020), %

83.6%

Net income (Q1, 2020)

(68.8m)

EBIT (Q1, 2020)

(58.4m)

Market capitalization (6-Jul-2020)

1.4b

Closing stock price (6-Jul-2020)

18.0

Cash (31-Mar-2020)

196.2m

EV

1.4b
Portola Pharmaceuticals's current market capitalization is $1.4 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

40.1m116.6m

Cost of goods sold

18.1m44.4m

Gross profit

22.0m72.3m

Gross profit Margin, %

55%62%
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

6.6m4.0m14.2m22.2m28.4m36.8m26.4m

Cost of goods sold

7.2m5.0m2.7m4.3m

Gross profit

15.0m23.4m34.1m22.1m

Gross profit Margin, %

68%82%93%84%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

117.8m57.5m186.5m188.5m181.6m139.0m215.2m

Accounts Receivable

309.0k57.0k1.0m3.8m5.8m13.5m

Prepaid Expenses

3.7m5.7m3.1m2.7m9.0m11.7m8.0m

Inventories

1.1m7.9m4.1m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

112.2m58.7m63.0m57.1m53.1m132.8m68.9m77.7m210.7m139.3m98.7m135.7m123.8m344.0m168.4m173.1m146.7m226.8m185.4m304.3m196.2m

Accounts Receivable

3.5m227.0k6.7m182.0k73.0k12.0k7.5m5.0m11.8m14.0m18.2m7.4m

Prepaid Expenses

4.0m3.7m5.2m5.0m4.7m12.0m16.0m20.5m3.3m5.3m4.6m3.3m12.3m8.8m14.6m6.8m5.3m9.7m9.4m10.1m10.4m

Inventories

3.2m7.1m6.1m2.7m1.5m2.4m3.6m
USDQ2, 2013

Financial Leverage

1.1 x
Show all financial metrics

Portola Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Portola Pharmaceuticals Online and Social Media Presence

Embed Graph

Portola Pharmaceuticals Company Culture

  • Overall Culture

    C+

    76/100

  • CEO Rating

    A+

    90/100

  • Compensation

    A+

    95/100

Learn more on Comparably

Portola Pharmaceuticals News and Updates

Global Allergic Conjunctivitis Market (2020 to 2027) - Featuring Santen Pharmaceutical, Alcon, Portola Pharmaceuticals and Ocular Therapeutix Among Others

Dublin, April 13, 2021 (GLOBE NEWSWIRE) -- The "Allergic Conjunctivitis Market, Global Forecast Treated Patients By Countries, Disease Type, Pipeline Drugs, Company Analysis" report has been added to ResearchAndMarkets.com's offering. Allergic conjunctivitis is common ophthalmic disorder caused by…

PORTOLA 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Portola Pharmaceuticals, Inc. - PTLA

NEW ORLEANS, March 15, 2020 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until March 16, 2020 to file lead plaintiff applications in securities class action lawsuits...

Portola LOSS NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Reminds Portola Pharmaceuticals, Inc. Investors of Important March 16th Deadline in Securities Class Action

NEW YORK, Feb. 10, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Portola Pharmaceuticals, Inc. between November 5, 2019 and January 9, 2020, inclusive (the "Class Period"), of the important March 16, 2020 lead plaintiff...

ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Portola Pharmaceuticals, Inc. - PTLA

NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) between November 5, 2019 and January 9, 2020, inclusive (the...

Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019

SOUTH SAN FRANCISCO, Calif., July 17, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended June 30, 2019, and provide a general business overview, ...

Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer, will present a corporate overview at the following investor conferences in June:
Show more

Portola Pharmaceuticals Blogs

U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year

- Reinforcing Breakthrough Innovation and Clinical Value of Andexxa, Proposed Extension Will Support Patient Access by Continuing to Provide Medicare Reimbursement in the Hospital Setting -

Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

- Reached Agreement to be Acquired by Alexion; Transaction Expected to Close in Third Quarter -

Alexion to Acquire Portola

– Expands and diversifies Alexion’s hematology, neurology and critical care commercial portfolio with transformative Factor Xa inhibitor reversal agent –

Portola Pharmaceuticals Announces the Establishment of a Permanent J-code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020

Portola Pharmaceuticals Announces the Establishment of a Permanent J-code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020 Content Import Tue, 04/07/2020 - 08:01 Portola Pharmaceuticals Announces the Establishment of a Permanent J-code for Andexxa by …
Show more

Portola Pharmaceuticals Frequently Asked Questions

  • When was Portola Pharmaceuticals founded?

    Portola Pharmaceuticals was founded in 2003.

  • Who are Portola Pharmaceuticals key executives?

    Portola Pharmaceuticals's key executives are Scott Garland, Mardi C. Dier and Sheldon Koenig.

  • How many employees does Portola Pharmaceuticals have?

    Portola Pharmaceuticals has 324 employees.

  • What is Portola Pharmaceuticals revenue?

    Latest Portola Pharmaceuticals annual revenue is $116.6 m.

  • What is Portola Pharmaceuticals revenue per employee?

    Latest Portola Pharmaceuticals revenue per employee is $360 k.

  • Who are Portola Pharmaceuticals competitors?

    Competitors of Portola Pharmaceuticals include Acceleron Pharma, Alembic Pharmaceuticals and EMS Pharma.

  • Where is Portola Pharmaceuticals headquarters?

    Portola Pharmaceuticals headquarters is located at 270 E Grand Ave, South San Francisco.

  • Where are Portola Pharmaceuticals offices?

    Portola Pharmaceuticals has offices in South San Francisco, Planegg and Amsterdam.

  • How many offices does Portola Pharmaceuticals have?

    Portola Pharmaceuticals has 3 offices.